$GOVX

GeoVax Labs (GOVX) supports a new global mpox vaccine stockpile initiative, funded by Gavi and WHO. The stockpile aims to provide equitable access to vaccines during outbreaks. GeoVax's CEO highlights the need for durable procurement and sufficient supply. The company's GEO-MVA vaccine candidate is advancing toward a Phase 3 study in 2026, with key milestones already achieved. GeoVax seeks to contribute to global supply resilience.

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Announces a Warrant Inducement Transaction ATLANTA, GA – August 26, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an e

GeoVax Labs (GOVX) announced a warrant inducement transaction with an institutional investor. The investor will exercise existing warrants to purchase up to 5.7 million shares at $0.64 per share, generating approximately $3.65 million in proceeds. In return, the investor will receive new warrants for up to 11.4 million shares. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on August 27, 2026, subject to customary

GeoVax Labs (GOVX) selected a CRO and European clinical sites for its Phase 3 study of GEO-MVA, a vaccine against mpox and smallpox. The study, planned for Q4 2026, will enroll 500 healthy adults and compare GEO-MVA's immunogenicity and safety to a licensed MVA vaccine. GeoVax aims to announce results by mid-2027, with the study's success potentially supporting EMA approval.

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

GeoVax (Nasdaq: GOVX) said it is highlighting its MVA-based hemorrhagic fever vaccine expertise amid a rapidly expanding Ebola outbreak in the DRC caused by Bundibugyo virus. The WHO reports 4,300+ cases and 2,000 deaths, with no approved BDBV vaccine. GeoVax plans to start a pivotal GEO-MVA immunobridging program in 2H 2026.

GeoVax Labs (Nasdaq: GOVX) said the FDA accelerated approval of TUDRIQEV (formerly RP1) plus nivolumab for unresectable advanced cutaneous melanoma after prior anti-PD-1 therapy supports momentum for intratumoral, tumor-directed immunotherapies. GeoVax highlighted its investigational Gedeptin tumor-priming approach and cited JCI Insight preclinical data showing enhanced immune responses with anti-PD-1. The company plans a next-phase study with pembrolizumab in head and neck cancer.

GeoVax Labs (NASDAQ:GOVX) says it plans to start a pivotal Phase 3 trial of its GEO-MVA mpox and smallpox vaccine before end-2024. The EMA granted an expedited pathway, waiving Phase 1 and 2, requiring an immunobridging study versus Bavarian Nordic’s MVA-BN. GeoVax cites a ~15 million dose annual MVA supply gap and targets government stockpiles.

GeoVax Labs (Nasdaq: GOVX) said it completed manufacturing, regulatory, clinical and preclinical milestones for its GEO-MVA pivotal Phase 3 immune-bridging study, scheduled to start in Q4 2026. The company expects a 500-participant trial and to report results in mid-2027, comparing GEO-MVA immune responses with licensed MVA-BN (Imvanex).

GeoVax Labs (GOVX) reported Q2 2026 net loss of $4.43M, or $0.97 per share, and cash of about $3.1M at June 30, 2026. Revenue was $0 after termination of a prior BARDA contract. The company said it is preparing to start a pivotal GEO-MVA immunobridging study in Q4 2026 and advancing its Gedeptin program.